---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003381"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:36:19.467988+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit

## Summary
- Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
- Total gross proceeds ~$4.0M; net proceeds ~$3.5M after underwriting discount and expenses.
- Closing occurred April 27-28, 2026 with full over-allotment exercise; 1,650,716 common shares, 1,312,247 pre-funded warrants, 3,407,404 warrants issued.
- Warrants exercisable at $1.35 per share for five years; Underwriters' warrants for 5% of sold securities at 110% of offering price.
- Net proceeds to be used for general corporate purposes including working capital.

## SEC filing metadata
- accession: 0001683168-26-003381
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316826003381/0001683168-26-003381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316826003381/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003381
- JSON: https://secwatch.observer/filing/0001683168-26-003381.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003381.txt

## Source-grounded claims
- claim_id: 63919a4dd75196dc793593e767fb09d7dd251531
  claim: Sonoma Pharmaceuticals, Inc. entered into Underwriting Agreement with Dawson James Securities, Inc. (effective 2026-04-24).
  evidence_excerpt: On April 24, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc. (the “Underwriter”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367083/000168316826003381/0001683168-26-003381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.